Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.
about
Melanized fungi in human diseaseInfections caused by Scedosporium spp.SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGYScedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist*In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungiIn vitro activities of four novel triazoles against Scedosporium sppSusceptibility of filamentous fungi to voriconazole tested by two microdilution methodsScedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.Disseminated infection caused by Scedosporium prolificans in a patient with acute multilineal leukemiaComparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species.In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatumAntifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999.Primary central nervous system phaeohyphomycosis: a review of 101 cases.It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drugDisseminated phaeohyphomycosis: review of an emerging mycosis.Review of the safety and efficacy of voriconazole.Voriconazole: a new triazole antifungal agent.Voriconazole in the management of nosocomial invasive fungal infections.Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanideSusceptibility and diversity in the therapy-refractory genus scedosporiumCytotoxicity of voriconazole on cultured human corneal endothelial cellsMycetoma medical therapy.Scedosporium species infections and treatments.Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.Human phagocytic cell responses to Scedosporium apiospermum (Pseudallescheria boydii): variable susceptibility to oxidative injuryTreatment of scedosporiosis with voriconazole: clinical experience with 107 patientsScedosporium apiospermum infection after near-drowning.Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis.Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi.When primary antifungal therapy fails.Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases.Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.Emerging infectious endocarditis due to Scedosporium prolificans: a model of therapeutic complexity.Emerging moulds: epidemiological trends and antifungal resistance.In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates
P2860
Q24633163-EC8EDD15-4151-4B02-979D-DE6070A7D3B0Q24657691-3EBEDFD8-25C5-48AF-9775-993F7D2DB06AQ26783197-45863C4E-8D3B-45BA-9CAE-67E2A39B01A5Q28315344-AE3650C6-2238-49BA-9A9F-952098D682AAQ28355507-E71FC355-ABB4-4E1E-959B-45062FA457ABQ28366842-4463B0D9-9FEF-4F6A-90E3-556A3A0CFBCEQ33592487-67892942-596D-40EF-B805-FFCF7A5271E0Q33824506-2157D8FF-66FB-4C19-9C7A-7DBA1F7E0C69Q33966663-FF52C00C-BBF5-4AE0-ADAE-80AA096A0585Q33971884-F2A0CFAA-7B4E-4F40-B103-43FE9644ABF8Q33972814-AFB35713-43C3-4D5D-9861-76F4B2541F65Q33978865-707DB8F3-3A16-4556-8BEA-0C4F070311C3Q33979873-ECF69F5D-B47C-417C-BBAB-90D9437E1E2DQ34109768-08E7596E-7BCA-4589-B84C-83318B4D549DQ34143259-02FDC509-134E-4D41-B4FB-ADC77E8E1EB4Q34202213-78F2C63E-FFEF-42B7-B0E5-77A75BC96215Q34243482-B3B572E4-5232-474B-BEE9-164C45699F44Q34286912-B87FE316-3F60-43AA-907F-C6429D27F45EQ34302880-DD18731C-9604-45BC-BB8A-D95CFDBA9A7DQ34498615-F9C96C6A-49D4-4F60-BE9F-65542B8B86ABQ34544679-AEC94914-37B5-455D-8754-641493946FC0Q35069136-8A464BDE-02B1-4E3E-9A89-81B7D5D0545EQ35166823-3E690877-27B5-45BC-AAC0-E1BC07D11AFAQ35194598-D18059D2-4CDA-4250-8BB8-E5C94022FB1EQ35214490-1C7C06D3-CECD-4B85-9C52-09EDE405F23CQ35270872-26137453-41BD-40B8-BE2A-E161969C3F90Q35351362-2E9A7280-673E-4AC4-8F0F-924E9A140308Q35622016-FC73AE9F-BEF1-4DE8-953B-00CE82996906Q35715408-6A134D6C-6064-49BE-8789-F612348E9E8BQ36376608-D13896EC-5CF9-406B-BF1C-E69BFDA7F5A2Q36593781-B151FB68-418E-46F5-8A4D-66854D55EEE0Q36917112-1204836F-3969-48DF-99C4-5C7DFC8263A3Q36933405-CA9A4DFB-C50D-4510-B50A-A01477327162Q37058525-AD618605-A52D-46EC-BD0A-4DB00D2B3967Q37141191-D0840D5D-47F5-4111-A087-766B900C1475Q37334205-49EB72BE-EB2E-4AF0-822B-B97F0E28B4D2Q37810091-7E460005-D9D6-41F2-BB53-485B63A8E7FBQ37860189-4E9411C1-5277-4BE9-BB62-B302C69970E4Q37889387-AA8EC783-3118-485A-8265-38C30008479EQ39650951-12C9B863-0468-437F-862D-D5D317CF6685
P2860
Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Comparative in-vitro activity ...... and Scedosporium apiospermum.
@en
Comparative in-vitro activity ...... and Scedosporium apiospermum.
@nl
type
label
Comparative in-vitro activity ...... and Scedosporium apiospermum.
@en
Comparative in-vitro activity ...... and Scedosporium apiospermum.
@nl
prefLabel
Comparative in-vitro activity ...... and Scedosporium apiospermum.
@en
Comparative in-vitro activity ...... and Scedosporium apiospermum.
@nl
P2093
P2860
P356
P1476
Comparative in-vitro activity ...... and Scedosporium apiospermum.
@en
P2093
Cuenca-Estrella M
Martínez-Suárez JV
Rodríguez-Tudela JL
Ruiz-Díez B
P2860
P304
P356
10.1093/JAC/43.1.149
P407
P577
1999-01-01T00:00:00Z